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Background
There is currently no international consensus for first-line treatment (prior to autologous stem
cell transplantation) in mantle cell lymphoma patients. Here, we investigated the efficacy and
tolerance of VAD associated with chlorambucil (VAD+C) and rituximab or not before autolo-
gous stem cell transplantation. 
Design and Methods
Between 1996 and 2005, 113 previously untreated mantle cell lymphoma patients were
enrolled in two consecutive prospective phase II studies. Responses and response factors to the
(R)VAD+C regimen were evaluated. The survival prognostic value of the MIPI score and Ki67
were also analyzed.
Results
The induction phase of 4 courses of (R)VAD+C showed very low hematologic and extra-hema-
tologic toxicity (grade 3-4 thrombopenia and neutropenia, 9% and 2.7%, respectively and
grade 3-4 extra-hematologic toxicities, 1.6%). Overall and complete response rates were 73%
and 46%, respectively, and rose to 83% and 51% for the 70% of patients with less than two
independent response factors (LDH, B symptoms and lymphocytosis). At the end of treatment,
65% of patients were in complete remission. Progression free and overall survival were signif-
icantly better in the transplanted population. The MIPI score was confirmed as a predictor of
survival. Ki67, serum LDH, Performance Status (PS) and B symptoms were identified as inde-
pendent prognostic factors of survival. A prognostic scoring system could stratify patients into
three risk groups with markedly different median overall survival of 112, 44 and 11 months,
respectively.
Conclusions
The (R)VAD+C is an effective regimen with very low toxicity. In addition to the MIPI score,
Ki67 expression provides additional independent prognostic information for the prediction of
overall survival (ClinicalTrials.gov Identifier: NCT00285389). 
Key words: autologous stem cell transplantation, mantle cell lymphoma, chlorambucil.
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Introduction
Mantle cell lymphoma (MCL) is an aggressive form of
lymphoma described in the international WHO classifica-
tion.1 Over the last decade the median overall survival
(OS) for MCL patients has risen from 3-4 years to five
years.2 A much shorter survival is, however, associated
with some histological subtypes, such as blastic variants
where median OS is 14 months compared to 53 months
for the common forms.3
There is currently no consensual front-line therapy for
MCL. Prior to the introduction of rituximab, and despite
the non-superiority of regimens containing anthracy-
clines,4,5 the CHOP regimen was initially widely used as
the reference treatment in view of its efficacy in aggressive
large B-cell lymphoma. Reported overall response (OR)
and complete remission rates (CR) range from 57 to 92%,
and 7 to 30%, respectively.6-8 High-dose cytarabine-based
regimens, such as DHAP8 or Hyper-CVAD,9 have been
shown to achieve better responses; around 95% OR and
between 38% and 84% CR, respectively.9,10 However,
higher toxicities make these regimens difficult to complete
in elderly patients.
Several reports have demonstrated that high-dose con-
solidation therapy including autologous stem cell trans-
plantation (auto-SCT) improves PFS8,9,11-15 This was con-
firmed by the European MCL network in a randomized
prospective phase III study.16 Auto-SCT associated to rit-
uximab treatment of molecular relapse has been shown to
extend median OS to five years.17
Here we report the long-term follow-up results of two
French GOELAMS studies which evaluated the tolerance
and efficacy of the VAD+C regimen with or without rit-
uximab in a total of 113 newly diagnosed MCL patients.18
The prognostic value of the recently-devised MIPI score19
and Ki67 expression status were also evaluated.
Design and Methods
Study design
The designs of the LM 1996 and LM2001 trials are summarized
in Figure 1. The goal of LM 1996 was to evaluate the efficacy and
tolerance of the VAD+C regimen.18 This trial was opened for
patients aged between 18 and 75 years old. The primary objective
of LM2001 was to evaluate the association of rituximab to the
VAD+C, in terms of efficacy and toxicity in patients under 65
years of age.
In LM1996, all patients underwent an induction phase of treat-
ment including 4 cycles of the VAD+C regimen. The VAD regi-
men (vincristine 0.4 mg/d, doxorubicine 9 mg/m2/d infused intra-
venously over four days associated with dexamethasone 20
mg/12h intravenous (IV) or oral (PO) administration on days 1 to
4) was applied every five weeks (d1 to d1) and associated with ten
days of chlorambucil 12 mg/d PO from day 20 to day 29 of each
cycle.18 Responses were evaluated after four cycles. All patients
showing more than a partial response (over 50%) were eligible for
the second phase. During this second phase, patients under 61
years of age received 2 additional cycles of the VAD+C regimen
followed four weeks later by high-dose melphalan (140 mg/m2)
and a fractioned total body irradiation (TBI) (8 grays, 4 fractions)
with peripheral blood stem cell (PBSC) support. The fourth VAD
cycle did not contain chlorambucil to limit the risk of harvest fail-
ure. Patients over 61 years not eligible for high-dose therapy
received 4 additional cycles of VAD+C. 
In the LM2001 trial, all 39 patients received the VAD+C induc-
tion associated to rituximab, (375 mg/m2, at day 1 of each cycle).
PBSC collection was performed as for LM1996 with, in addition,
high-dose cyclophosphamide (4 g/m2), mobilization (one course)
and in vivo purging with one injection of rituximab (375 mg/m2).
Prior to autologous transplantation, patients received one cycle of
RVAD+C and one cycle of VAD+C. The preparative regimen for
transplant was identical to that used in the LM1996 trial.
Patients’ selection
From 1996 to 2005, 113 newly diagnosed, previously untreated
mantle cell lymphoma patients (according to the WHO classifica-
tion1) were enrolled in the two consecutive phase II trials by the
French GOELAMS group described above. Ninety patients were
included in LM1996 (inclusions proceeded from September 1996
through December 2000) and 39 patients in the LM2001 trial
(from September 2003 through December 2005). Additional inclu-
sion criteria were an Ann Arbor (AA) stage II-IV and a perform-
ance status (PS) between 0 and 2 according to the ECOG scale.
Ann Arbor staging was based on clinical examination, CT scan,
bone marrow biopsy and gastric endoscopy. Peripheral blood infil-
tration was assessed by lymphocyte count. Patients were required
to have normal renal (creatinine clearance > 50 mL/mn), cardiac
(ventricular ejection fraction > 50%) and hepatic (ASAT/ALAT < 3
times the upper limit) functions. Patients with positivity for HIV,
HCV or HBV, or reporting a previous malignancy, were not includ-
ed. These phase II studies were approved by the ethics committee
of Grenoble University Hospital and by the GOELAMS institu-
tional review board (IRB). All recruited patients provided written
informed consent.
Tumor analysis
The initial pathological examination prior to inclusion was per-
formed locally and included morphological analysis and immuno-
histochemical detection of at least CD20 expression. All diagnoses
were reviewed centrally by 3 pathologists from the GOELAMS
pathology panel. MCL were classified, according to the criteria of
the WHO 2001 classification of Lymphoma, in two groups: the
common group with two variants (small cells and marginal zone-
like cells) and the blastoid group with the lymphoblastic-like and
the pleomorphic variants.
A total of 127 tumors were reviewed (83 lymph nodes and 44
extranodal tissues as follows: bone marrow n=18, spleen n=11,
gastrointestinal (GI) tract n=8, tonsils n=3, skin n=1, orbital tumor
n=2, salivary gland n=1).
Immunohistochemistry was performed using a labeled strepta-
vidin-biotin-peroxydase system with diamino-benzidin as chro-
mogen (Ultra-tech, Beckman Coulter, Miami, FL, USA). The fol-
lowing monoclonal antibodies were used: anti-CD5 (Novocastra,
Newcastle upon Tyne, UK), anti-CD23 (Novocastra), anti-IgD
(Dako, Glostrup, Denmark) anti-cyclin D1 CCND1 (Novocastra)
and anti-Ki67 (Novocastra). In the LM1996 study, Ki67 immunos-
taining and quantification were performed by counting a total of
one thousand cells in two areas of high Ki67 expression (2x500).
The mean Ki67 count (26%) was used as the cut-off that could dis-
tinguish two different prognostic groups. In the 2001 trial, Ki67
was quantified by counting 2x250 cells also showing high CCND1
expression. If this first count yielded 20-30% Ki67 positivity
(approaching the cut off of 26%), an additional observation of
2x250 cells was performed to confirm the initial count. 
Evaluation and response criteria
Physical examination and complete blood cell count (CBC) pre-
ceded each course of (R)VAD. A CT scan was performed after the
induction phase and after completion of the treatment plan. A
(R)VAD and chlorambucil for first line treatment of MCL
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bone marrow aspiration was also performed at these check-
points. Subsequently, follow up was performed every three
months during the first year and then every six months, including
physical examination and CBC counts each time. CT scans were
repeated every six months and bone marrow biopsies once year-
ly. Response was defined according to the International Working
Group criteria.20
Statistical and prognostic factor analyses
Sixteen parameters were analyzed as potential adverse prognos-
tic factors for response rate: age at diagnosis (<61 years vs. ≥61
years), sex, pathology subtype (common form vs. blastoid vari-
ants), lymphocytosis at diagnosis (<5¥109/L vs. ≥5¥109/L), PS
(ECOG 0-1 vs. 2), B symptoms, LDH serum level (Normal vs. > N),
bulky tumor (maximal diameter <10 cm vs. ≥10cm), number of
extranodal sites (<2 vs. ≥2), bone marrow infiltration, GI tract
localization, spleen localization, rituximab administration or not,
and Ki67 status. Response rate after the induction phase (<50% vs.
≥50%) and auto-SCT (yes vs. no) were also studied as prognostic
factors of survival.
A logistic regression was applied with the SPSS (Chicago, IL,
USA) software to identify which factors impacted on the response
rate. According to the international response criteria,21 the proba-
bility of overall survival (OS) was calculated for all patients from
day one of the first cycle, until death, and the probability of pro-
gression free survival (PFS) until death or progression. OS and PFS
were plotted with the StatView software (1998 SAS institute Inc.).
Cox’s regression analysis with the forward stepwise method was
applied with all factors, except the response after induction phase,
to establish which clinical or biological factors at diagnosis impact-
ed independently on OS and/or PFS. The log rank test was used to
validate an index, determined by independent factors, which was
compared with the MIPI score. P values lower than 0.05 were con-
sidered significant.
Results
Patients’ characteristics
Patients’ characteristics are summarized in Table 1.
After pathology review and control of the inclusion/exclu-
sion criteria, 74 patients were included in the LM1996 and
all 39 patients of the LM2001 trial were considered eligi-
ble for the study. Fourteen patients of the 129 initially
selected (15%) were excluded because of initial misdiag-
nosis (7 patients diagnosed as B chronic lymphocytic
leukemia, 4 follicular and 3 marginal zone lymphoma).
Two other patients presented exclusion criteria.
Eighty-five patients (75%) were diagnosed as common
MCL and 27 (24%) with a blastoid variant. One patient
could not be classified because only a bone marrow biop-
sy was available. 
There were 84 males and 29 females (ratio 2.9). All but
4 patients had stage III-IV disease (n=109, 96%). There
was bone marrow involvement in 88% of the patients
(99/113) and 60% (68/113) showed spleen involvement,
16% (18/113) head/neck or orbit involvement and 18%
(20/113) a GI localization (3 with polyposis). Fifty-nine
percent of the patients had more than one extranodal site
localization. Bulky tumor, defined by a diameter larger
than 10 cm, was present in 23% of the cases and 39% of
the cases displayed B symptoms. A PS over 1 was
observed for 9% of the patients; 38% had increased LDH
serum levels. Lymphocytosis over 5¥109/L was observed
in 31% of the patients and Ki67 over the defined thresh-
old in 43%. According to the MIPI score, 47% (n=52/110)
of the patients were in the low-risk group, 31%
(n=34/110) in the intermediate group and 22% (n=24/110)
in the high-risk group. There was no statistically signifi-
cant difference in clinical and biological characteristics
between the patients receiving the VAD+C regimen with-
out rituximab and those who received rituximab (Table 1).
Seventy-eight patients (70%, 78/113) were considered, at
diagnosis, to be eligible for intensive therapy, i.e. 39
patients in each trial.
(R)VAD+C toxicity
Of the 414 VAD+C cycles performed during the induc-
tion phase (including rituximab in 150 cycles), 18 (4%)
were delayed. WHO grade 3-4 neutropenia and throm-
bopenia were seen after 35 cycles (8%) and 11 cycles
(3%), respectively. Fifteen patients required red blood cell
(n=13) or platelet (n=9) transfusion during this phase. All
presented with anemia or thrombopenia at diagnosis. The
most serious extra-hematologic side effects consisted of
WHO grade 3-4 infections (n=8), grade 3 cardiac side-
effects (n=2) and grade 3 transaminase alterations (n=1).
Fifty-eight patients had at least one WHO Grade 1-2 gas-
trointestinal, infectious, neurological, or cardiac side-
effects. No renal complications were reported.
Response rates after 4 (R)VAD+C (induction phase)
Overall (ORR) and complete (CR/CRu) response rates
after 4 cycles of (R)VAD+C were 73% (n=82) and 46%
(n=52), respectively. There were no differences in ORR or
CR/CRu between the VAD+C and R-VAD+C regimen
(73% vs. 72% for ORR and 49% vs. 44% for CR/Cru,
respectively). ORR and CR/CRu did not differ between
young (n=78) and elderly patients (n=35): ORR was 70.5%
(55/78) and 77% (27/35) (P=0.46) and CR/CRu was 44%
(34/78) and 48% (17/35) (P=0.62). Thirty-one patients
(27%) were not eligible for the second phase: one patient
died, 12 did not achieve partial response (PR), and 18 pro-
gressed while on therapy. The median OS of these
patients was ten months. 
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Figure 1. Study design of the LM 1996 and LM 2001 trials and num-
ber of responders at the intermediate and final step of evaluation.
N= number of patients recruited in each arm. VAD+C: vincristine 0.4
mg/D, D1 to D4; doxorubicin 9 mg/m2/D, D1 to D4; dexamethasone
40 mg/D, D1 to D4; chlorambucil 12 mg/D, D20 to D29 ; 2 cycle
delay 35 days. RVAD+C: rituximab 375 mg/m2, D1 of each VAD
cycle. H1 and H2: stem cell harvest; H1, steady state manner; H2,
cyclophosphamide mobilization 4 g/m2 and in vitro purge with ritux-
imab 375 mg/m2. 2(R)VAD+C*, one RVAD+C followed by one
VAD+C. §Melphalan 140 mg/m2 and TBI 8 gy/4 fractions.
Induction
phase
LM 1996
N=74
LM 2001
N=39
> 60 years
N=35
4 VAD+C
4 VAD+C
n=31
2VAD+C
auto-SCT§
n=23
2R-VAD+C*
auto-SCT§
n=26
2R-VAD+C
n=2
4 VAD+C 4R-VAD+C
Yes
n=27
Yes
n=27
Yes
n=28
No
n=8
No
n=12
No
n=11
n=4 n=2
H1 H2
< 60 years
N=39
< 65 years
N=39
Response>50%
n=82
Second
phase
Stem cell collection was performed in 52 young
patients. A median of 2 cytaphereses were necessary to
collect an average 3.46¥106 CD34+ cells/kg (0.9-11.5):
3.34¥106 CD34+ cells/kg (0.9-10.7) in LM1996 and
5.94¥106 CD34+ cells/kg (2.02-11.5) in LM2001. Harvest
failed in 3 patients.
Response rate at the end of the treatment plan
Out of the 82 responding patients, 33 were not trans-
planted. Among them, 31 received a total of 8 cycles of
VAD+C without rituximab (27 elderly and 4 young
patients of LM 1996) and 2 young patients of LM 2001
received a total of 6 cycles of R-VAD+C. 
Forty-nine young patients were transplanted: 23 of
LM1996 patients received 6 cycles of VAD+C and 26 of
LM2001 patients received 6 cycles of R-VAD+C before
auto-SCT. Six patients did not receive the scheduled auto-
SCT because of stem cell mobilization failure (n=3), pro-
tocol violation (n=1), coronary thrombosis (n=1) or
metastatic carcinoma (n=1).
For the 33 patients treated with (R)VAD+C alone, dis-
ease status at the end of treatment was CR/CRu in 29
cases (88%), PR in one case and three progressions. For the
49 transplanted patients, the disease status at the end of
the treatment was CR/CRu in 44 cases (89%), PR in 3
cases, one progression and one death. In summary, 73 of
the 113 patients (66%) were in CR/CRu after the end of
treatment.
Overall survival and progression free survival
The final analyses were performed in December 2007
and September 2009 for LM 1996 and LM 2001, respec-
tively. The median follow up (FU) for the 39 living patients
was 62 months (104 and 53 months, respectively, for
LM1996 and LM2001 patients). The 3-year OS rate of the
113 patients was 62% (IC 95%, 46-68%) and median OS
was 52 months. For the 78 young patients, the 3-year OS
rate was 66.5% with a median OS of 63 months while for
the 35 elderly patients treated with 8 VAD+C without rit-
uximab these values were 51% and 36 months, respec-
tively (Figure 2A). OS was significantly better for the 49
transplanted patients compared to 64 non-transplanted
patients: 3-year OS=81% (95%CI, 50-90%) vs. 47%
(95%CI, 37 to 56%) P<0.0001 (Figure 2B). The PFS was
also significantly better for patients who received auto-
SCT: 3-year FS = 62% (95%IC, 28-68%) vs. 6% (95% IC,
2-12%) P<0.0001 (Figure 2C).
For the 35 elderly patients, 3-year PFS and median PFS
were 11% and 16 months, respectively. For the 49 trans-
planted patients there was a trend to a better PFS for those
receiving rituximab prior to auto-SCT (P=0.054) (Figure
3A) which did not translate into a better OS (P=0.49)
(Figure 3B). 
Response factors to the induction phase
and prognostic factors for survival
Predictive factors of response to the 4 cycles of induc-
tion were analyzed. Logistic regression analyses identified
three independent factors: LDH (P=0.009), B symptoms
(P=0.007) and lymphocytosis (P=0.05). The ORR and
CR/CRu between 78 patients (70%) with few adverse
response factors (RF) (0 or 1) and 35 patients (30%) with
high RF (2 or 3) were statistically different: ORR 83% with
few RF vs. 47% with high RF (P=0.001) and CR/CRu 51%
for few RF vs. 31% (P=0.047). 
We next analyzed prognostic factors (PF) influencing
OS. In a monoparametric analysis, eight PF had a signifi-
cant impact: response to the induction phase, auto-SCT,
PS, lymphocytosis more than 5¥109/L, presence of B
symptoms, elevated LDH, spleen involvement and Ki67
expression. In a multiparametric Cox’s regression model,
four independent PF influenced OS: LDH level, Ki67 pro-
liferation index, PS and B symptoms. It is, therefore, pos-
sible to propose a “GOELAMS index” of MCL prognostic
factors related to the number of pejorative PF observed at
diagnosis within these four criteria: Ki67>26%, ECOG>1,
B symptoms and LDH>N. This allowed an OS prognostic
index to be defined that stratified patients into three sta-
tistically significant distinct risk groups (Figure 4A,
P<0.0001): group 1 (16 patients with 3-4 PF) with a medi-
an OS of 11 months, group 2 (64 patients with 1-2 PF)
with a median OS of 44 months and group 3 (33 patients
without any PF) with a median OS of 112 months. 
The MIPI score, applied to 110 patients of our cohort,
was efficient in distinguishing three independent prognos-
tic groups: the high-risk group (n=24) had a median OS of
20 months, the intermediate group (n=34) had a median
OS of 42 months and the low-risk group (n=52) had a
median OS of 75 months (Figure 4B). 
Discussion 
In this study, 113 previously untreated mantle cell lym-
phoma patients were enrolled into two consecutive phase
II prospective studies in order to explore the efficacy and
tolerance of the VAD+C regimen, previously tested in
(R)VAD and chlorambucil for first line treatment of MCL
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Table 1. Patients’ and tumor characteristics.
Clinical presentation n/N (%) n/N (%) P
Trial LM2001 LM1996
N=39 N=74
Sex, male 27/39 (70) 57/74 (77) ns
Ann Arbor Stage III-IV 36/39 (92) 73/74 (98) ns
Bone marrow infiltration 35/39 (89) 64/74 (86) ns
Spleen localization 24/39 (61) 44/72 (60) ns
GI tract localization 8/39 (20) 12/74 (16) ns
Head and neck localization 3/39 (8) 12/74 (16) ns
Extra nodal sites >1 23/39 (59) 43/73 (59) ns
Bulky > 10 cm 8/39 (20) 18/74 (24) ns
ECOG status > 1 2/39 (5) 8/73 (11) ns
B symptoms 15/39 (39) 29/74 (39) ns
LDH level > N 16/39 (42) 27/72 (37) ns
Lymphocytes > 5¥109/L 9/39 (23) 26/74 (35) ns
MIPI low ; int ; high (%) 58;29;13 42;32;26 ns
Tumor characteristics
Blastoid subtype 12/39 (31) 15/73 (21) ns
CD5 positive 35/39 (90) 72/74 (97) ns
CD10 negative 25/25 (100) 66/66 (100) ns
CD23 negative 36/37 (97) 65/69 (94) ns
BCL1 positive 28/29 (97) 68/74 (92) ns
Ki67 > 26% 14/33 (42) 30/70 (43) ns
n, number of patients with informative characteristics; N, number of patients studied. GI,
gastro-intestinal; ECOG, Eastern Cooperative Oncology Group; LDH, lactatehydroge-
nase; ns , not statistically significant (P>0.05).
relapsed patients,18 with or without addition of rituximab.
With 73% and 46% ORR and CR rates, respectively, 4
cycles of the (R)VAD+C compared favorably with 6 cycles
of CHOP.8,16 However 70% of our patients (n=78) with
less than 2 independent response factors integrating LDH
level, B symptoms and lymphocyte count had response
rates close to 6 cycles of RCHOP22,23, with a more favor-
able toxicity profile (Table 2). Moreover, the median OS
(36 months) and PFS (16 months) of our 35 elderly patients
treated with 8 cycles of VAD+C without rituximab was
similar to that reported in the literature with 6 CHOP or 6
RCHOP cycles.22,23 Rituximab did not improve the
response rate of the VAD+C regimen in this study. One
reason could be a trend to a higher MIPI score for patients
treated with rituximab (Table 1). Indeed, rituximab has
been reported to improve all other regimens in first line
(CHOP, DHAP or HyperCVAD) (Table 2).22,24,26 As expect-
R. Gressin et al.
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Figure 2. (A) Overall Survival (OS) as intent to treat of 78 young and
35 elderly patients receiving first-line (R)VAD+C regimen followed or
not by auto-SCT. (B) Overall survival. (C) Progression free survival, of
the 49 transplanted patients (Tr) versus 64 non-transplanted
patients (no Tr).
Figure 3. (A) Progression free survival and (B) overall survival, of the
transplanted patients after RVAD+C or VAD+C regimen.
Figure 4. (A) Overall survival according to the GOELAMS index relat-
ed to the number of criteria observed at diagnosis among 4 pejora-
tive prognostic factors (PF): Ki67>26%, ECOG>1, B symptoms and
LDH>N. g1 = group with 3 or 4 PF, g2 = group with 1 or 2 PF and g3
= group without PF. (B) Overall survival according to the MIPI,
Low=low-risk, Int = intermediate-risk and High = high-risk. 
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ed, the efficacy was lower than that observed for high-
dose cytarabine-containing regimens R-Hyper-CVAD or
R-DHAP.8,24,25 However, the low toxicity profile observed
means the (R)VAD+C regimen offers a good efficacy/tol-
erance ratio particularly recommended for elderly
patients. RVAD+C has to be compared with other combi-
nation regimens which have shown a good efficacy in first
line for elderly patients. The RFC regimen is currently
compared to RCHOP in a phase III study of the EU MCL
network. The British national cancer research network is
completing a phase II trial that compares FC with or with-
out rituximab in order to evaluate the impact of rituximab
in non-transplanted MCL patients. Of note, the ben-
damustin-rituximab (BR) regimen has shown a good effi-
cacy/toxicity profile on indolent lymphoma including
MCL in relapse and was recently reported as effective as
RCHOP in first line.27,28
This study confirms that intensive strategies including
auto-SCT prolong PFS, as previously demonstrated in a
randomized study conducted by the European MCL net-
work.16 We also demonstrated a better OS in transplanted
patients; but these were non-randomized trials and the
populations of transplanted and non-transplanted patients
differed by age. The 3-year OS and PFS rates (81% and
62%, respectively) of the 49 transplanted patients were
comparable to those previously published.8,16,17,26 Unlike
the recent study previously reported by the Nordic group,
no survival plateau was observed in our study.17 The use of
rituximab before auto-SCT seemed to give a PFS advan-
tage as recently reported.29,30 We also observed, as pub-
lished by Murali et al., long-term relapses with up to ten
years of follow up in patients who did not benefit from
auto-SCT.31 In this setting, maintenance therapy strategies
or treatment of molecular relapses as recently published
are of particular interest.32
In addition to confirming the prognostic value of the
MIPI score, this work shows that additional important
prognostic information can be obtained from quantifying
Ki67 expression, in agreement with recent studies from
the EU MCL network and German low-grade lymphoma
study group (GLSG).19 Recent recommendations to assess
the Ki67 index have been published by the MCL net-
work.33 We used very similar screening procedures for
Ki67 evaluation. Ki67 expression, together with three
additional parameters available at diagnosis (PS > 1, pres-
ence of B symptoms, elevated serum LDH), was combined
into a new scoring system that proved particularly power-
ful for the identification of very high- and low-risk
patients, respectively. Of note, the 26% threshold for Ki67
expression is very close to that (30%) reported by the EU
MCL network and the GLSG.34 The very high-risk group
could benefit from more intensive treatment strategies
such as allogeneic stem cell transplantation which has
shown promise in relapsed MCL.35-37 Conversely, low-risk
patients could benefit from less intensive (continuous)
treatment regimens, and the (R)VAD+C could be a good
option in this setting.38
In conclusion, this study demonstrates the low toxicity
and efficacy of the (R)VAD+C regimen as first-line thera-
py in mantle cell lymphoma patients. This regimen can be
considered an efficient therapeutic option especially for
elderly patients and for low-risk younger patients sched-
uled to undergo auto-SCT. However, it is reasonable to
propose that younger patients would benefit from more
intensive treatment programs such as R-DHAP or
RmaxiCHOP-RHDAraC followed by auto-SCT.17,25
Refinement of the current prognostic scoring systems for
MCL could be very useful to accurately assign MCL
patients to appropriate treatment plans as early as possi-
ble, particularly in the younger patient group.
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